EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+16.08%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$1.69B
AUM Growth
+$1.69B
(+0.21%)
Cap. Flow
-$21.8M
Cap. Flow
% of AUM
-1.29%
Top 10 Holdings %
Top 10 Hldgs %
77.4%
Holding
50
New
6
Increased
5
Reduced
4
Closed
14
Top Buys
| 1 |
iTeos Therapeutics
ITOS
|
$107M |
| 2 |
Zymeworks
ZYME
|
$71.7M |
| 3 |
Galapagos
GLPG
|
$24.7M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$18.9M |
| 5 |
Alkermes
ALKS
|
$14.3M |
Top Sells
| 1 |
Prothena Corp
PRTA
|
$143M |
| 2 |
Sarepta Therapeutics
SRPT
|
$82.5M |
| 3 |
Oric Pharmaceuticals
ORIC
|
$18.3M |
| 4 |
Beam Therapeutics
BEAM
|
$10.3M |
| 5 |
Ginkgo Bioworks
DNA
|
$8.34M |
Sector Composition
| 1 | Healthcare | 99.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Zymeworks
ZYME
$1.12B
| $288M | 17.06% | 22,970,388 +5,710,840 | +33% | +$71.7M |
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $206M | 12.19% | 11,895,808 | – | – |
|
3
Jazz Pharmaceuticals
JAZZ
$7.75B
| $181M | 10.72% | 1,706,469 | – | – |
|
4
AnaptysBio
ANAB
$569M
| $175M | 10.36% | 7,880,094 | – | – |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $123M | 7.3% | 4,288,120 | – | – |
|
|
6
iTeos Therapeutics
ITOS
| $107M | 6.31% | +10,688,978 | New | +$107M |
|
7
CRISPR Therapeutics
CRSP
$4.71B
| $67.6M | 4% | 1,389,276 | – | – |
|
8
uniQure
QURE
$896M
| $55.6M | 3.29% | 3,988,971 | – | – |
|
9
Tango Therapeutics
TNGX
$747M
| $54.4M | 3.22% | 10,630,736 | – | – |
|
10
Xencor
XNCR
$580M
| $48.3M | 2.86% | 6,144,767 | – | – |
|
11
Immunome
IMNM
$828M
| $37.9M | 2.25% | 4,079,415 | – | – |
|
12
Janux Therapeutics
JANX
$1.37B
| $34M | 2.01% | 1,469,818 | – | – |
|
|
13
Galapagos
GLPG
$2.07B
| $29M | 1.72% | 1,036,945 +881,939 | +569% | +$24.7M |
|
14
Eton Pharmaceutcials
ETON
$464M
| $28.9M | 1.71% | 2,030,544 +91,256 | +5% | +$1.3M |
|
15
Kura Oncology
KURA
$686M
| $24.2M | 1.43% | 4,200,000 +1,559,702 | +59% | +$9M |
|
16
Akero Therapeutics
AKRO
$3.74B
| $23.5M | 1.39% | 440,000 | – | – |
|
17
Madrigal Pharmaceuticals
MDGL
$9.76B
| $22.7M | 1.34% | 75,000 | – | – |
|
18
Neurogene
NGNE
$264M
| $19M | 1.13% | 1,271,342 | – | – |
|
|
VRNA
19
Verona Pharma
VRNA
$9.16B
| $18.9M | 1.12% | +200,000 | New | +$18.9M |
|
|
TECX
20
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $18.6M | 1.1% | 935,121 | – | – |
|
|
21
Oric Pharmaceuticals
ORIC
$994M
| $16.4M | 0.97% | 1,618,068 -1,800,000 | -53% | -$18.3M |
|
|
22
Alkermes
ALKS
$4.78B
| $14.3M | 0.85% | +500,000 | New | +$14.3M |
|
23
Avidity Biosciences
RNA
$5.99B
| $14.2M | 0.84% | 500,000 -57,576 | -10% | -$1.64M |
|
|
MBX
24
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $13.1M | 0.78% | 1,149,794 -109,479 | -9% | -$1.25M |
|
25
Voyager Therapeutics
VYGR
$186M
| $12.2M | 0.72% | 3,917,546 | – | – |
|